Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Journal of Scleroderma and Related Disorders is Scopus-indexed (Q3, CiteScore 2.6), WoS ESCI. It is covered by India's One Nation One Subscription scheme for reading access. Published by SAGE Publications Ltd.
Checked against the index lists dated .
ISSN 2397-1983Verify ISSN ↗2397-1991Verify ISSN ↗
Publisher: SAGE Publications Ltd
Cost to publish: About US$4,150 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Rheumatology | 48 / 77 | 38th | Q3 |
| Immunology and Allergy | 167 / 234 | 28th | Q3 |
| Immunology | 183 / 243 | 24th | Q4 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2016–2025, best quartile Q3, CiteScore 2.6.
Journal of Scleroderma and Related Disorders is Q3 in Rheumatology (rank 48 of 77), Q3 in Immunology and Allergy (rank 167 of 234) and Q4 in Immunology (rank 183 of 243), by CiteScore 2025.
Journal of Scleroderma and Related Disorders is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2.6, which places it in quartile Q3 at the 38th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.631, quartile Q2, with an H-index of 30.
The publisher lists an article processing charge of about US$4,150 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Journal of Scleroderma and Related Disorders is published by SAGE Publications Ltd. Its print ISSN is 2397-1983 and its online ISSN is 2397-1991.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Emerging Sources Citation Index.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Journal of Scleroderma and Related Disorders has an h-index of 34 and a 2-year mean of 1.75 citations per paper (OpenAlex). Its Scopus CiteScore is 2.6, quartile Q3. On 2-year citations it ranks #36 of 74 Scopus journals in Rheumatology.
Journal of Scleroderma and Related Disorders published 53 papers in 2025; its busiest recent year was 2018 with 66. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2024–2026), authors are most often from United States (27.4%), United Kingdom (13.9%) and Italy (10.6%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.